Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-65.
週五，強生（NYSE:JNJ）宣佈停止評估調查中的二期現場研究，該研究評估了候選抗病毒藥物mosnodenvir在年齡在18-65歲之間的成年人中預防登革病毒的療效。
The decision to discontinue this study is part of a strategic reprioritization of the company's Communicable Diseases research and development (R&D) portfolio. No safety issues were identified.
停止進行這項研究的決定是該公司傳染病研究和發展（研發）組合的戰略重排序的一部分。沒有發現安全問題。
Efficacy data from the Phase 2 field study will be available once the final data analyses, which are now underway, are complete.
二期現場研究的有效性數據將在最終數據分析完成後提供，目前正在進行這項工作。
Also Read: Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug.
另請閱讀：強生的Erleada在與輝瑞藥物相比的前列腺癌患者中顯示出改善的總生存率。
Mosnodenvir (formerly JNJ-1802) was shown to be safe and well tolerated in previous Phase 1 and Phase 2a clinical studies.
以前的一期和二期a臨床研究顯示，mosnodenvir（原JNJ-1802）的安全性和耐受性良好。
In October 2023, results from the Phase 2a human challenge study found that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo.
2023年10月，二期a人體挑戰研究的結果發現，與安慰劑相比，該化合物引起人體對登革病毒（DENV-3）的抗病毒活性。
The study evaluated different dosing regimens – low, medium or high – of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults.
該研究評估了對健康成年人中的弱化登革熱3（DENV-3）採用JNJ-1802的不同劑量方案-低劑量，中劑量或高劑量。
All participants received daily doses of JNJ-1802 or a placebo over 26 days, during which they were challenged with DENV-3 on day 5.
所有參與者在26天內每天接受JNJ-1802或安慰劑的劑量，期間他們在第5天接受了DENV-3的挑戰。
All participants were monitored over 85 days. The study found a dose-dependent antiviral effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo and was safe and well-tolerated.
所有參與者在85天內接受監測。研究發現與安慰劑相比，存在劑量依賴的抗病毒效果，可減少DENV-3 RNA的可檢測性和首次可檢測到DENV-3 RNA的時間，並且安全且耐受良好。
In May, Takeda Pharmaceutical Co Ltd's (NYSE:TAK) dengue vaccine received World Health Organization's (WHO) prequalification.
5月，武田製藥股份有限公司（紐約證券交易所：TAK）的登革熱疫苗獲得世界衛生組織（WHO）預認證。
TAK-003 is the second dengue vaccine to be prequalified by WHO.
TAk-003是第二款獲得世界衛生組織預認證的登革熱疫苗。
WHO recommended using TAK-003 in children aged 6–16 in settings with high dengue burden and transmission intensity.
世衛組織建議在登革熱負擔和傳播強度高的情況下，使用TAk-003疫苗接種6-16歲的兒童。
Price Action: JNJ stock is down 0.60% at $159.53 at the last check on Friday.
股價走勢：截至上週五最新檢查，強生股價下跌0.60%，報159.53美元。
- Lucid Air Electric Vehicles Join Blink Charging's Envoy Program: Details.
- 露騎士Air新能源車加入blink charging的使者計劃：詳細信息。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。
